Back to search
FDAFDA · Food and drugs·Recall number D-0270-2019

GSMS Irbesartan Tablets, USP, 75 mg, 30-count bottle, Rx Only, Manufactured by ScieGen Pharmaceuticals, Inc. Hauppauge, NY 11788 Marketed by: GSMS Incorporated Camarillo, CA 93012 USA, NDC 60429-640-90.

Published November 28, 2018 · Recall initiated: October 29, 2018

Summary

FDA records drug Class II recall D-0270-2019, published November 28, 2018 and initiated October 29, 2018. Recalling firm: Sciegen Pharmaceuticals Inc; Status: Terminated; Reported quantity: 3,835 HDPE bottles; Lot: 60429-640-90 Irbesartan 75mg Tablets, 90 Count Bottle B160003 Sep-19 B160004 Sep-19. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Sciegen Pharmaceuticals Inc
Distributor
Nationwide
Lot
60429-640-90 Irbesartan 75mg Tablets, 90 Count Bottle B160003 Sep-19 B160004 Sep-19
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was GSMS Irbesartan Tablets, USP, 75 mg, 30-count bottle, Rx Only, Manufactured by ScieGen Pharmaceuticals, Inc. Hauppauge, NY 11788 Marketed by: GSMS Incorporated Camarillo, CA 93012 USA, NDC 60429-640-90. recalled?

Yes. FDA published recall D-0270-2019 on November 28, 2018. Reported hazard: CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release